ArticleMolecular pain
Mechanism of asiatic acid in relieving psoriasis by modulating the PI3K/Akt/NF-κB pathway and NLRP3 inflammasome.
Article in Molecular pain. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this paper is to expound the effect of asiatic acid (AA) on psoriasis via modulating the PI3K/Akt/NF-κB pathway and NLRP3 inflammasome.
methodsAn imiquimod (IMQ)-induced psoriasis model in BALB/c mice was established. Mice were divided into the control, IMQ, and AA treatment groups with different doses. Psoriasis area and severity were scored using the Psoriasis Area Severity Index (PASI). Histological changes, inflammatory factor levels in skin lesions, and expressions of NLRP3 inflammasome-related proteins and pathway proteins were measured. For cellular experiments, HaCaT cells were classified into control, model, AA low and high concentration groups, and AA-H + IGF group. Cells were stimulated with IL-17A, IL-22, TNF-α, IL-1α, and OSM (M5) to induce psoriasis-like conditions, followed by treatment with AA or IGF. Cell viability, oxidative stress levels, inflammatory factors, NLRP3 expression, and PI3K/Akt/NF-κB pathway protein levels were assessed.
resultsIn vivo, IMQ-induced mice showed psoriasis-like symptoms, including increased PASI scores, IL-6, TNF-α, IL-17A, and NLRP3-related protein levels. AA treatment alleviated these symptoms, reducing NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), and Caspase-1 expression, and restraining the PI3K/Akt/NF-κB pathway phosphorylation. In cellular experiments, M5 induction impeded cell viability and advanced oxidative stress, IL-1β, IL-6, and NLRP3 expression, activating the PI3K/Akt/NF-κB pathway. AA markedly reversed these change.
conclusionAA alleviates psoriasis symptoms by blocking the PI3K/Akt/NF-κB pathway and NLRP3 inflammasome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.